<DOC>
	<DOCNO>NCT02623049</DOCNO>
	<brief_summary>Background : The incidence atrial fibrillation ( AF ) increase substantially age estimate one third AF patient octogenarian . Direct oral anticoagulant ( DOACs ) find favorable compare warfarin respect efficacy safety ( bleed ) across wide range age . Nevertheless , rate bleed among elderly patient show increase substantially anticoagulant . Dose-adjustments DOAC universally perform among patient older 80 year old currently paucity data regard actual drug level among patient . Accordingly , investigator seek investigate drug level different DOACs among `` real world '' octogenarian receive guideline-recommended dosage . Methods : A cross sectional , prospective study 120 hospitalized ambulatory patient treat DOACs AF . DOACs blood level compare octogenarian ( n=70 ) young patient group ( age≤70 year-old ; n=50 ) .The cohort include : 1 ) Sixty patient APIXABAN : 40 octogenarian 20 young 70 year , 2 ) Forty patient RIVAROXABAN : 20 octogenarian 20 young 70 year , 3 ) Twenty patient treated DABIGATRAN : 10 octogenarian 10 young 70 year . DOACs Pharmacodynamic analysis perform use commercial kit dilute thrombin time ( DTT ) anti-factor Xa activity ( AFXa ) . Drug level measure steady state ( level ) Tmax least 4 day complete adherence DOAC consumption . Study End-Points : The study main objective : 1 ) DOACs level octogenarian comparison patient young 70 year 2 ) percentage patient , group , target DTT AFXa ( predict ) steady state . Potential significance study : The result study may provide new data DOACs level octogenarians thus would either support current recommendation set ground study aim optimize DOACs dosage vulnerable population .</brief_summary>
	<brief_title>Direct Oral Anticoagulants Pharmacodynamics Octogenarian Patients With Atrial Fibrillation</brief_title>
	<detailed_description>A cross sectional , prospective study hospitalize ambulatory patient , treat DOACs AF . Patient population Candidate study patient older 80 year ( octogenarian ) ≤70 year 1 ) admit Internal Medicine division Rabin Medical Center Beit Rivka rehabilitation hospital treatment DOAC prior hospitalization \ rehabilitation , 2 ) hospitalize patient DOAC initiate hospitalization 3 ) refer ambulatory patient DOACs . Each potential patient screen age risk factor bleed ( specifically require dose adjustment renal failure , weight , potentially interact drug ) DOAC treatment . Study cohorts The investigator plan assess DOACS level among 120 patient treat one three available agent : Group 1 ) sixty patient treat direct Xa inhibitor Apixaban - 40 octogenarian 20 young 70 year . Group 2 ) forty patient treat direct Xa inhibitor Rivaroxaban - 20 octogenarian 20 young 70 year Group 3 ) twenty patient treat direct Thrombin inhibitor Dabigatran - 10 octogenarian patient receive age-adjusted recommend reduced dosage ( 110 mg bid ) 10 patient young 70 year . Decision continue and/or initiate DOAC well dosage , discretion treat physician . Patients prescribed dosage accord current recommendation exclude , unless appropriate adjustment make prior enrolment . Informed consent obtain patient prior study enrolment . Patient 's demographic data document baseline include : age , sex , body weight height , comorbidities , concurrent medication , blood test result ( complete blood count , INR , aPTT , renal function test , electrolytes liver enzymes ) . CHA2DS2-VASc HAS-BLED risk score calculate enrolled patient . Actual body weight determine upon recruitment standardize , calibrate scale . DOACs pharmacodynamic analysis perform use commercial kit DTT AFXa . Drug level measure steady state ( level ) Tmax ( time maximum serum peak concentration observe ) . DTT AFXa sample least 4 day complete adherence DOAC consumption . In case hospitalize patient , drug level obtain prior patient discharge . The steady state sample take morning dose ( trough level ) . Maximal DTT AFXa ( Tmax ) determine blood sample take 2 hour morning dose dabigatran 3 hour Apixaban/Rivaroxaban . All blood sample draw patient clinical condition stable differ his/her baseline daily status ( include stable kidney function ) . In addition , adherence prescribe dosage DOAC least 4 consecutive day assure prior blood sampling . Accordingly , hospitalize patient may discharge invite later ward drug level sample base discretion enrol physician ( example , case questionable adherence last 4 day allow full recovery significant change medical condition ) . All blood sample study draw attend physician . The blood sample ( 2 tube 3 ml ) cod collect 3.2 % citrate tubes measurement pharmacodynamic effect , perform Beilinson hospital coagulation lab . The cod system base patient drug treatment . Dabigtran , Rivaroxaban Apixaban sample cod first letter generic drug name run serial number ( D-1,2,3… ) . Immediately collection , tube transfer coagulation lab , invert achieve complete mix centrifuge 10 min 3000xg . Platelet-poor plasma transfer label transfer tube store -20°C . The sample keep coagulation lab freezer two month collection . Chromogenic anti Xa assay analysis perform thaw sample use commercial assay ( Liquid anti Xa , Instrumentation Laboratory , MA , USA ) . Diluted thrombin time assay perform sample use commercial assay ( Hemoclot Thrombin Inhibitors , Hyphen Biomed , France ) . Inclusion criterion : - Octogenarian group : Age ≥ 80 year . - Younger age group : Age ≤ 70 year . - Previous diagnosis non-valvular atrial fibrillation / flutter new diagnosis , document electrocardiography - CHA2DS2-VASc score ≥1 . - Hemodynamically stable patient ( i.e. , without cardiogenic shock circulatory collapse ) . - Receiving DOACs least 4 day . - Stable renal function . Exclusion criterion : - Patients expect stop DOACs within 4-8 day ( i.e . plan operation invasive procedure ) - Patients require dose adjustment DOACs base clinical judgment manufacturer recommendation ( i.e . acute renal function deterioration GFR le 30 ml/min , need dual antiplatelet therapy ) - History gastrointestinal condition could significantly impact drug absorption ( Crohn 's disease , gastrectomy ) . - A history recent drug alcohol abuse - Concomitant treatment combine strong P-gp inhibitor CYP3A4 inhibitor drug ( : grapefruit juice , itraconazole , lopinavir/ritonavir , clarithromycin , ritonavir , ketoconazole , indinavir/ritonavir , conivaptan ) . - Concomitant treatment combine strong P-gp inducer CYP3A4 inducer drug ( : avasimibe , carbamazepine , phenytoin , phenobarbital , rifampin , St John 's wort ) - Estimated glomerular filtration rate &lt; 30 ml/min - Patients elevate liver enzyme ALT/AST &gt; 3 x ULN total bilirubin ≥ 1.5 x ULN . - Weight &gt; 120 kg . - Pregnant woman . Study termination criterion : •None . Study duration- The study expect duration 2 year . Statistical analysis - The sample size study choose provide cohort large enough identify difference group , base previous study . Descriptive statistic use calculate summary data . Data represent mean ± SD median [ 5th , 95th percentile ] , unless otherwise indicate . Parametric , two-tailed Student 's t-tests ANOVA use continuous variable χ2 Fisher 's exact test categorical variable predetermine alpha level P &lt; 0.05 . Statistical analysis perform use SAS statistical software ( version 8.2 , SAS Institute , Cary , NC ) .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Atrial Flutter</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Octogenarian group : Age ≥ 80 year . Younger age group : Age ≤ 70 year . Previous diagnosis nonvalvular atrial fibrillation / flutter new diagnosis , document electrocardiography CHA2DS2VASc score ≥1 . Hemodynamically stable patient ( i.e. , without cardiogenic shock circulatory collapse ) . Receiving DOACs least 4 day . Stable renal function . Patients expect stop DOACs within 48 day ( i.e . plan operation invasive procedure ) Patients require dose adjustment DOACs base clinical judgment manufacturer recommendation ( i.e . acute renal function deterioration GFR le 30 ml/min , need dual antiplatelet therapy ) History gastrointestinal condition could significantly impact drug absorption ( Crohn 's disease , gastrectomy ) . A history recent drug alcohol abuse Concomitant treatment combine strong Pgp inhibitor CYP3A4 inhibitor drug ( : grapefruit juice , itraconazole , lopinavir/ritonavir , clarithromycin , ritonavir , ketoconazole , indinavir/ritonavir , conivaptan ) . Concomitant treatment combine strong Pgp inducer CYP3A4 inducer drug ( : avasimibe , carbamazepine , phenytoin , phenobarbital , rifampin , St John 's wort ) Estimated glomerular filtration rate &lt; 30 ml/min Patients elevate liver enzyme ALT/AST &gt; 3 x ULN total bilirubin ≥ 1.5 x ULN . Weight &gt; 120 kg . Pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>New oral anticoagulant</keyword>
	<keyword>Blood level</keyword>
	<keyword>Octogenarians</keyword>
</DOC>